TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8594693

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Fansidar (pyrimethamine‐sulfadoxine)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 600
Study: 2483435

Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d.)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ibopamine (200 mg t.i.d.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 4423243

Group type: EXPERIMENTAL
Intervention: Permissively worded amnesia suggestions with hypnotic motivation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Authoritatively worded amnesia suggestions with hypnotic motivation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Permissively worded amnesia suggestions with waking motivation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Authoritatively worded amnesia suggestions with waking motivation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Permissively worded amnesia suggestions with waking nonmotivation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Authoritatively worded amnesia suggestions with waking nonmotivation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Task motivating procedures
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Non task motivating procedures
Number of subjects: 120
Study: 31113688

Group type: EXPERIMENTAL
Intervention: Personalized 3D printed models
Number of subjects: 45

Group type: COMPARATOR
Intervention: CT & MRI imaging (care-as-usual)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 3D reconstructions
Number of subjects: 45
Study: 28662692

Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee arthroplasty (MB TKA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Fixed-bearing total knee arthroplasty (FB TKA)
Number of subjects: 106
Study: 26222557

Group type: EXPERIMENTAL
Intervention: Hypothermia (34 to 35°C)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Normothermia (36.5 to 37.5°C)
Number of subjects: 370
Study: 23911260

Group type: EXPERIMENTAL
Intervention: LX4211
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21282130

Group type: EXPERIMENTAL
Intervention: Canine scent detection of breath samples
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Canine scent detection of stool samples
Number of subjects: 70
Study: 19807925

Group type: EXPERIMENTAL
Intervention: Outpatient Schema Therapy (ST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapist telephone availability outside office hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 17219155

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microm every 6 h for a maximum of 24 h)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel (0.5 mg every 6 h for a maximum of 24 h)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel
Number of subjects: 130
Study: 15650341

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (100 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Estrogen replacement therapy (0.625 mg conjugated estrogen)
Number of subjects: 30
Study: 11525087

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study: 10223394

Group type: EXPERIMENTAL
Intervention: MMPP mouth-rinse and dentifrice
Number of subjects: 131

Group type: COMPARATOR
Intervention: MMPP dentifrice
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: MMPP rinse and dentifrice with SLS
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 2026667

Group type: EXPERIMENTAL
Intervention: Terbutaline (a selective beta‐2 agonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dilevalol (a new non‐selective beta‐blocker with beta‐2 agonist activity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (N Saline)
Number of subjects: 12
Study: 6318353

Group type: EXPERIMENTAL
Intervention: Bi-Profenid 300 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oxyphenbutazone 400 mg
Number of subjects: 44
Study: 31868813

Group type: EXPERIMENTAL
Intervention: 16 weekly sets per muscle group (G16)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 24 weekly sets per muscle group (G24)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 32 weekly sets per muscle group (G32)
Number of subjects: 27
Study: 31901649

Group type: EXPERIMENTAL
Intervention: Delirium group
Number of subjects: 187

Group type: COMPARATOR
Intervention: Non-delirium group
Number of subjects: 187
Study: 31226888

Group type: EXPERIMENTAL
Intervention: Manual dissection
Number of subjects: 376

Group type: COMPARATOR
Intervention: Femtosecond laser
Number of subjects: 376
Study: 30217048

Group type: EXPERIMENTAL
Intervention: Aerobic activity program
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Combination of physical activity and Low Glycemic Index Mediterranean Diet (LGIMD)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Dietary intake of omega-3 PUFAs with healthy lifestyle
Number of subjects: 142
Study: 27488368

Group type: EXPERIMENTAL
Intervention: Behaviorally oriented guided self-help program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nondirective guided self-help program
Number of subjects: 110
Study: 23959116

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control CCBs
Number of subjects: 45
Study: 21378215

Group type: EXPERIMENTAL
Intervention: Learning carbohydrate counting
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Learning carbohydrate counting (per-protocol analysis)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Estimating pre‐meal insulin dose (control)
Number of subjects: 61
Study: 19637541

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (without shortwave diathermy)
Number of subjects: 97
Study: 17567306

Group type: EXPERIMENTAL
Intervention: Cosmetic care
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 16871748

Group type: EXPERIMENTAL
Intervention: Cimetidine (3 x 200 mg + 400 mg after 12 h)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Single 400 mg dose of cimetidine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Famotidine 40 mg
Number of subjects: 76
Study: 11858102

Group type: EXPERIMENTAL
Intervention: Plasmapheresis + withdrawal of long‐acting nitrate
Number of subjects: 85

Group type: COMPARATOR
Intervention: Withdrawal of nitrates only
Number of subjects: 85
Study: 9917431

Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP) 6.0 micromol/kg birth weight, single dose, intramuscular
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no SnMP)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sn-mesoporphyrin (SnMP)
Number of subjects: 84
Study: 8014496

Group type: EXPERIMENTAL
Intervention: Alternating combination regimen of chronic ganciclovir-foscarnet therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Concurrent combination regimen of chronic ganciclovir-foscarnet therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (adjunctive therapy)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination therapy (ganciclovir-foscarnet)
Number of subjects: 29
Study: 2689574

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 gm intravenously at the time of clamping of the cord
Number of subjects: 646

Group type: COMPARATOR
Intervention: Cefotetan 2 gm intravenously at the time of clamping of the cord
Number of subjects: 646
Study: 788002

Group type: EXPERIMENTAL
Intervention: Lithium sulphate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29384322

Group type: EXPERIMENTAL
Intervention: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) with two green kiwifruit
Number of subjects: 33

Group type: COMPARATOR
Intervention: Daily isoflavone supplementation (50 mg/day aglycone daidzein and genistein) alone
Number of subjects: 33
Study: 29141692

Group type: EXPERIMENTAL
Intervention: HomeStyles intervention
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Survey completers
Number of subjects: 489
Study: 25430687

Group type: EXPERIMENTAL
Intervention: rTMS (110% motor-threshold; rightDLPFC, 1000 stimuli at 1 Hz + leftDLPFC, 1000 stimuli at 10 Hz)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: theta-burst stimulation (80% motor-threshold; rightDLPFC, continuous TBS, 1200 stimuli + leftDLPFC, intermittent TBS, 1200 stimuli)
Number of subjects: 56

Group type: COMPARATOR
Intervention: sham TMS (sham coil with the TBS protocol)
Number of subjects: 56
Study: 23790989

Group type: EXPERIMENTAL
Intervention: Incentive Group (n=199) using a loyalty card to collect points and earn rewards for PA
Number of subjects: 406

Group type: COMPARATOR
Intervention: No Incentive Group (n=207) using a loyalty card for self-monitoring without incentives
Number of subjects: 406
Study: 20973908

Group type: EXPERIMENTAL
Intervention: FreeHand® robotic camera holder
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual camera control by human assistant
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (FreeHand® and manual control)
Number of subjects: 50
Study: 18410350

Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16213066

Group type: EXPERIMENTAL
Intervention: Replication defective herpes simplex virus vaccine (gH deletion) administered at 0 and 8 weeks, or 0, 4, and 8 weeks, or 0, 2, 4, and 8 weeks.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Daily sample collection for asymptomatic viral shedding
Number of subjects: 74
Study: 12958082

Group type: EXPERIMENTAL
Intervention: Rivastigmine (acute administration)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 21
Study: 10718203

Group type: EXPERIMENTAL
Intervention: Metrifonate (125-225 mg loading dose for 2 weeks, followed by 50-90 mg maintenance dose for 4 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 39
Study: 9172970

Group type: EXPERIMENTAL
Intervention: Cognitive behavior intervention (1 to 6 sessions)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual medical‐social care (control group)
Number of subjects: 132
Study: 8491328

Group type: EXPERIMENTAL
Intervention: Ayre spatula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ayre spatula plus endocervical cytobrush
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervexbrush
Number of subjects: 0
Study: 2959925

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 31974770

Group type: EXPERIMENTAL
Intervention: Individual Meaning-Centered Psychotherapy-Palliative Care (IMCP-PC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Counselling-based psychotherapy
Number of subjects: 51
Study: 29362276

Group type: EXPERIMENTAL
Intervention: Integrated medicines management (IMM) intervention including medication reconciliation, review, counselling, medication list, and post-discharge calls.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Integrated medicines management (IMM) intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 500
Study: 27568215

Group type: EXPERIMENTAL
Intervention: Obiltoxaximab (16 mg/kg IV)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 25904041

Group type: EXPERIMENTAL
Intervention: BMS‐820836 2 mg once daily for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BMS‐820836 4 mg once daily for 14 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Encapsulated moxifloxacin 400 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 120
Study: 23645003

Group type: EXPERIMENTAL
Intervention: Total Disc Replacement (TDR)
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Lumbar Fusion
Number of subjects: 1603
Study: 21216314

Group type: EXPERIMENTAL
Intervention: Stocking at least one vaccine recommended for adults
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Plans to stop stocking vaccines
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Plans to increase vaccine purchases
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Stocking all adult vaccines
Number of subjects: 886
Study: 19063837

Group type: EXPERIMENTAL
Intervention: Herba Saxifragae cream (HS), applied externally twice a day for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hydrocortisone (HC), applied externally twice a day for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of total scores of symptom score reducing index (SSRI)
Number of subjects: 42
Study: 16938063

Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement (ME) group
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 285
Study: 14659852

Group type: EXPERIMENTAL
Intervention: Beta-radiation therapy (188Re-MAG3)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 10623957

Group type: EXPERIMENTAL
Intervention: Walking shoes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Barefoot
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dress shoes
Number of subjects: 35
Study: 9180166

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) treatment
Number of subjects: 9
Study: 8256309

Group type: EXPERIMENTAL
Intervention: Fermented milk product (200 ml daily for six weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (chemically acidified milk, 200 ml daily for six weeks)
Number of subjects: 58
Study: 3916041

Group type: EXPERIMENTAL
Intervention: 1 mg vaginal suppository of Gemeprost
Number of subjects: 180

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 180
Study: 29455756

Group type: EXPERIMENTAL
Intervention: Healthy Eating and Active Living Taught at Home (HEALTH) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27692413

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion using EDO
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyrax expander
Number of subjects: 50
Study: 25456365

Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg/week)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Anastrozole (1 mg/day)
Number of subjects: 1410
Study: 23200931

Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 10 μg/hour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 20 μg/hour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20965447

Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Adjunctive TMS
Number of subjects: 301

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 301
Study: 18329223

Group type: EXPERIMENTAL
Intervention: Extracurricular 12-step meetings
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Sober recreational events
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Educational sessions
Number of subjects: 733

Group type: COMPARATOR
Intervention: Residential program
Number of subjects: 733

Group type: COMPARATOR
Intervention: Day-hospital program
Number of subjects: 733
Study: 16154788

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12849674

Group type: EXPERIMENTAL
Intervention: Tezosentan 50 mg/h
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Tezosentan 100 mg/h
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 10566411

Group type: EXPERIMENTAL
Intervention: Web-delivered multimedia health educational program (Student Bodies)
Number of subjects: 0
Study: 8983555

Group type: EXPERIMENTAL
Intervention: Absorbable skin tacks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stainless steel staples
Number of subjects: 20
Study: 1832182

Group type: EXPERIMENTAL
Intervention: 2 micrograms intradermally (ID) in months 0, 1, 6
Number of subjects: 95

Group type: COMPARATOR
Intervention: 10 micrograms subcutaneously (sc) in months 0, 1, 6
Number of subjects: 95
Study: 458200

Group type: EXPERIMENTAL
Intervention: ADV‐4 vaccine
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: ADV‐7 vaccine (three vaccines group)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: ADV‐7 vaccine (two vaccines group)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (three vaccines group)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (one vaccine group)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study: 31976527

Group type: EXPERIMENTAL
Intervention: Increased BMI (≥ 28 kg/m2, quartile 4)
Number of subjects: 10805

Group type: EXPERIMENTAL
Intervention: Increased WC (≥ 91 cm for females, quartile 4)
Number of subjects: 10805

Group type: EXPERIMENTAL
Intervention: Increased WC (≥ 79 cm for males, quartile 2-4)
Number of subjects: 10805

Group type: EXPERIMENTAL
Intervention: Increased BMI and increased WC (joint analysis)
Number of subjects: 10805

Group type: EXPERIMENTAL
Intervention: Increased WC only
Number of subjects: 10805
Study: 30652262

Group type: EXPERIMENTAL
Intervention: Fixed dose combination of chlorzoxazone 500 mg and ibuprofen 400 mg (C + I group)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg (I group)
Number of subjects: 406
Study: 28830251

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham control (SHAM)
Number of subjects: 53
Study: 25027772

Group type: EXPERIMENTAL
Intervention: Motor control training (two 30-minute sessions per week for 7-8 weeks)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Motor control training
Number of subjects: 46
Study: 23011109

Group type: EXPERIMENTAL
Intervention: Perturbations delivered in multiple directions (forward, backward, left, right, and combinations)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Perturbations delivered in multiple directions (left and right)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Berg Balance Scale assessment
Number of subjects: 10
Study: 21426611

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Approach (CBA) training for health visitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Person-Centred Approach (PCA) training for health visitors
Number of subjects: 0
Study: 19345067

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNFalpha-antagonists
Number of subjects: 0
Study: 16960171

Group type: EXPERIMENTAL
Intervention: Tomato extract supplement drink (equivalent to 6 tomatoes)
Number of subjects: 23
Study: 15561391

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 36
Study: 11531665

Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied in supine position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied in 15 degrees lateral tilt
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cricoid pressure in supine position
Number of subjects: 50

Group type: COMPARATOR
Intervention: No cricoid pressure in 15 degrees lateral tilt
Number of subjects: 50
Study: 9248875

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam as needed every 30 min for 4 h
Number of subjects: 37

Group type: COMPARATOR
Intervention: 5 mg haloperidol as needed every 30 min for 4 h
Number of subjects: 37
Study: 8272247

Group type: EXPERIMENTAL
Intervention: G10‐3N dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: G120 M dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CD 4000 dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: T 150 dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Duo‐Flux dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: F 60 dialyser
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Filtral dialyser
Number of subjects: 37
Study: 3828167

Group type: EXPERIMENTAL
Intervention: Nasal intubation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral intubation
Number of subjects: 100
Study: 28951228

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir for 8 weeks
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir for 12 weeks
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 468
Study: 27888956

Group type: EXPERIMENTAL
Intervention: Individualized integrative nursing intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 60
Study: 23743961

Group type: EXPERIMENTAL
Intervention: Iron (II) sulfate (Fe2+), 5 mg Fe/kg/d
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Iron (III)-hydroxide polymaltose complex (Fe3+)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study: 23966142

Group type: EXPERIMENTAL
Intervention: Chester step test (CST)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Modified incremental step test (MIST)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6-MWT)
Number of subjects: 17
Study: 21227003

Group type: EXPERIMENTAL
Intervention: 5% sevoflurane
Number of subjects: 32

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 32
Study: 18418231

Group type: EXPERIMENTAL
Intervention: Homocysteinemia (>16 micromol/l)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Earlier acute coronary syndrome
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Early stroke
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: NSTEMI
Number of subjects: 124